Heparin: new life for an old drug (Q40164066)

18 September 2017

1 reference

title

Heparin: new life for an old drug (English)

1 reference

18 September 2017

1 reference

Carlos Raúl Aláez-Versón

series ordinal

1

1 reference

PubMed ID

28635544

18 September 2017

Elena Lantero

series ordinal

2

1 reference

PubMed ID

28635544

18 September 2017

Xavier Fernàndez-Busquets

series ordinal

3

1 reference

18 September 2017

21 June 2017

1 reference

18 September 2017

1 reference

18 September 2017

12

1 reference

18 September 2017

1727-1744

1 reference

18 September 2017

14

1 reference

William Henry Howell and Jay McLean: the experimental context for the discovery of heparin.

18 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The origin of the dispute over the discovery of heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The story of the discovery of heparin and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin and heparan sulfate: structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Bioengineered human heparin with anticoagulant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin-protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Pathophysiology of heparan sulphate: many diseases, few drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

USP compendial methods for analysis of heparin: chromatographic determination of molecular weight distributions for heparin sodium.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Lessons learned from the contamination of heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin and heparan sulfate: analyzing structure and microheterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Structural and haemostatic features of pharmaceutical heparins from different animal sources: challenges to define thresholds separating distinct drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Re-visiting the structure of heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparins from porcine and bovine intestinal mucosa: Are they similar drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Characterization of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Structural characterization of pharmaceutical heparins prepared from different animal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

An unusual antithrombin-binding heparin octasaccharide with an additional 3-O-sulfated glucosamine in the active pentasaccharide sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin dodecasaccharide containing two antithrombin-binding pentasaccharides: structural features and biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Antithrombin-binding oligosaccharides: structural diversities in a unique function?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Photochemical Preparation of a Novel Low Molecular Weight Heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Controllable production of low molecular weight heparins by combinations of heparinase I/II/III.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Structure and activity of a new low-molecular-weight heparin produced by enzymatic ultrafiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Low molecular weight heparins: Structural differentiation by spectroscopic and multivariate approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Pharmacology of Heparin and Related Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Recent advances in antithrombotic treatment for acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Anticoagulation in patients with impaired renal function and with haemodialysis. Anticoagulant effects, efficacy, safety, therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Old and new applications of non-anticoagulant heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Protease-proteoglycan complexes of mouse and human mast cells and importance of their beta-tryptase-heparin complexes in inflammation and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Assays and reference materials for current and future applications of heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The anti-inflammatory effects of heparin and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin: Past, Present, and Future

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Mast cells and IgE: from history to today

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Inhibition of allergic airway responses by heparin derived oligosaccharides: identification of a tetrasaccharide sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin normalizes allergen-induced nitric oxide deficiency and airway hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The effect of heparin on antigen-induced mucus hypersecretion in the nasal epithelium of sensitized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Inhaled heparin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Is inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Ascidian (chordate-tunicate) and mammalian heparin enemas attenuate experimental diversion colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Mechanisms of heparin induced anti-cancer activity in experimental cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin as an inhibitor of cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Alzheimer's disease: another target for heparin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Effect of heparin on APP metabolism and Abeta production in cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Sulfated polysaccharides promote the assembly of amyloid beta(1-42) peptide into stable fibrils of reduced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Glycosaminoglycans and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Amyloid formation by the model protein muscle acylphosphatase is accelerated by heparin and heparan sulphate through a scaffolding-based mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Modulation of Abeta42 fibrillogenesis by glycosaminoglycan structure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Amyloid fibrils in neurodegenerative diseases: villains or heroes?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Role of glycosaminoglycans in infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The pathogenic basis of malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The silent path to thousands of merozoites: the Plasmodium liver stage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Invasion of red blood cells by malaria parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Assessment of the RTS,S/AS01 malaria vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Public health challenges and prospects for malaria control and elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Chondroitin sulfate of thrombomodulin is an adhesion receptor for Plasmodium falciparum-infected erythrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Structural basis for binding of Plasmodium falciparum erythrocyte membrane protein 1 to chondroitin sulfate and placental tissue and the influence of protein polymorphisms on binding specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Inhibition of chondroitin-4-sulfate-specific adhesion of Plasmodium falciparum-infected erythrocytes by sulfated polysaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Saccharide anions as inhibitors of the malaria parasite.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Inhibition of Plasmodium falciparum growth in vitro and adhesion to chondroitin-4-sulfate by the heparan sulfate mimetic PI-88 and other sulfated oligosaccharides.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Plasmodium falciparum: a family of sulphated glycoconjugates disrupts erythrocyte rosettes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Biochemical and biophysical characterisation of DBL1alpha1-varO, the rosetting domain of PfEMP1 from the VarO line of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Complications of Falciparum Malaria and Their Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

New concepts in treatment of malignant tertian malaria with cerebral involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Intravascular coagulation in falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Sequence determination and anticoagulant and antithrombotic activities of a novel sulfated fucan isolated from the sea cucumber Isostichopus badionotus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Fucosylated chondroitin sulfate inhibits Plasmodium falciparum cytoadhesion and merozoite invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Marine organism sulfated polysaccharides exhibiting significant antimalarial activity and inhibition of red blood cell invasion by Plasmodium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Gellan sulfate inhibits Plasmodium falciparum growth and invasion of red blood cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Growth-inhibitory effect of a fucoidan from brown seaweed Undaria pinnatifida on Plasmodium parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Nanomimics of host cell membranes block invasion and expose invasive malaria parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Release of sequestered malaria parasites upon injection of a glycosaminoglycan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The effect of curdlan sulphate on development in vitro of Plasmodium falciparum.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Acquired immunity to malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

That Was Then But This Is Now: Malaria Research in the Time of an Eradication Agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Disrupting malaria parasite AMA1-RON2 interaction with a small molecule prevents erythrocyte invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Application of heparin as a dual agent with antimalarial and liposome targeting activities toward Plasmodium-infected red blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Novel hollow microcapsules based on iron-heparin complex multilayers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Advanced nanocarriers based on heparin and its derivatives for cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Controlling the complexation of polysaccharides into multi-functional colloidal assemblies for nanomedicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Single-step synthesis of heparin-doped polypyrrole nanoparticles for delivery of angiogenic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin-conjugated poly(lactic-co-glycolic acid) nanospheres enhance large-wound healing by delivering growth factors in platelet-rich plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Nanoneurobiophysics: new challenges for diagnosis and therapy of neurologic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Controlled release of chitosan/heparin nanoparticle-delivered VEGF enhances regeneration of decellularized tissue-engineered scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Sustained dual release of placental growth factor-2 and bone morphogenic protein-2 from heparin-based nanocomplexes for direct osteogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin nanomodification improves biocompatibility and biomechanical stability of decellularized vascular scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Fabrication of small-diameter vascular scaffolds by heparin-bonded P(LLA-CL) composite nanofibers to improve graft patency

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Cellular trafficking of low molecular weight heparin incorporated in layered double hydroxide nanoparticles in rat vascular smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

GSH-mediated photoactivity of pheophorbide a-conjugated heparin/gold nanoparticle for photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Physicochemical characterization of ferumoxytol, heparin and protamine nanocomplexes for improved magnetic labeling of stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin conjugated quantum dots for in vitro imaging applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The multiple complexes formed by the interaction of platelet factor 4 with heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Hyaluronan- and heparin-reduced silver nanoparticles with antimicrobial properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin sensing and binding - taking supramolecular chemistry towards clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Heparin micropatterning onto fouling-release perfluoropolyether-based polymers via photobiotin activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Call to action: priorities for malaria elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Antimalarial drug therapy: the role of parasite biology and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Nanotools for the delivery of antimicrobial peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Nanomedicine against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Novel strategies for Plasmodium-targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Nanotechnology applied to the treatment of malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Use of poly(amidoamine) drug conjugates for the delivery of antimalarials to Plasmodium.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Anti-malarial drug formulations and novel delivery systems: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Protein-heparin interactions measured by BIAcore 2000 are affected by the method of heparin immobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Demonstration of specific binding of heparin to Plasmodium falciparum-infected vs. non-infected red blood cells by single-molecule force spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Antigenic variation at the infected red cell surface in malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

VAR2CSA is the principal ligand for chondroitin sulfate A in two allogeneic isolates of Plasmodium falciparum.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

History, dynamics, and public health importance of malaria parasite resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The biology of sexual development of Plasmodium: the design and implementation of transmission-blocking strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The multifaceted mosquito anti-Plasmodium response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein: significance for malarial sporozoite attachment to hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

A small molecule glycosaminoglycan mimetic blocks Plasmodium invasion of the mosquito midgut

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Plasmodium falciparum ookinetes require mosquito midgut chondroitin sulfate proteoglycans for cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Plasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Antimalarial drug delivery to the mosquito: an option worth exploring?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Dominant lethality and insect population control.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Optimal life stage for radiation sterilization of Anopheles males and their fitness for release

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

The status of new anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

A Potential Nanomedicine Consisting of Heparin-Loaded Polysaccharide Nanocarriers for the Treatment of Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Structural peculiarity and antithrombin binding region profile of mucosal bovine and porcine heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

Combined Quantitative 1H and 13C Nuclear Magnetic Resonance Spectroscopy for Characterization of Heparin Preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM-2017-0127

21 January 2018

Identifiers

DOI

10.2217/NNM-2017-0127

1 reference

18 September 2017

1 reference

PubMed ID

28635544